Machine Learning for PK/PD Modeling in Drug Development
Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and…
Certara2025 年 3 月 4 日
How the US FDA MIDD paired pilot program helps sponsors
2025 年 2 月 28 日 For the past couple of decades, leading American institutions, pharmaceutical and biotechnology…
Certara2025 年 2 月 28 日
Gain Nonclinical Drug Safety Insights with Real-Time Data Analysis
2025 年 2 月 24 日 Efficient drug development relies on informed decision-making. For toxicologists, having timely access…
Certara2025 年 2 月 24 日
Measuring metabolites in index clinical DDI studies
2025 年 2 月 7 日A key drug development safety consideration is whether the drug candidate will interact…
Certara2025 年 2 月 7 日
Key development considerations for cell therapies
2024 年 12 月 5 日 What is a “cell therapy”? Nearly every recent oncology clinical conference has…
Certara2024 年 12 月 5 日
PBPK Modeling to Support Bioequivalence & Generic Product Approvals
Physiologically-based pharmacokinetic modeling can be used to support bioequivalence (BE) assessment of complex and locally…
Certara2024 年 11 月 12 日
The Future is Now: Virtual Clinical Trials Transforming Drug Development
Welcome to the forefront of drug development innovation! The drug development landscape is rapidly evolving,…
Certara2024 年 6 月 4 日
Phoenix UGM 2024: A Day of Innovation and Collaboration
The Phoenix UGM featured industry expert insights, peer networking, and glimpses into the latest PK/PD…
Certara2024 年 5 月 31 日
